NCT07309471 Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD
| NCT ID | NCT07309471 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | LSD Reaction |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2026-03-06 |
| Primary Completion | 2028-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2026-03-06 with a primary completion date of 2028-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigates DDH-LSD, a novel LSD-like compound expected to have a shorter duration of action than LSD. In healthy volunteers, pharmacokinetics, safety, and subjective effects, will be assessed and compare with LSD in a controlled cross-over study.
Eligibility Criteria
Inclusion Criteria: 1. Age between 25 and 65 years old 2. Sufficient understanding of the German language 3. Understanding of procedures and risks associated with the study 4. Willing to adhere to the protocol and signing of the consent form 5. Willing to refrain from the consumption of illicit psychoactive substances during the study 6. Abstaining from xanthine-based liquids from the evenings prior to the study sessions and during the sessions 7. Willing not to operate heavy machinery within 48 h of substance administration 8. Willing to use effective contraceptive measures throughout study participation 9. Body mass index between 18-32 kg/m2 Exclusion Criteria: 1. Chronic or acute medical condition 2. Current or previous major psychiatric disorder 3. Psychotic disorder or bipolar disorder in first-degree relatives 4. Hypertension (SBP\>140/90 mmHg) or hypotension (SBP\<85 mmHg) 5. Use of hallucinogenic substances (not including cannabis) more than 20 times or any time within the previous two months 6. Pregnancy or currently breastfeeding 7. Participation in another clinical trial (currently or within the last 30 days) 8. Use of medication that may interfere with the effects of the study medication 9. Tobacco smoking (\>10 cigarettes/day) 10. Consumption of alcoholic beverages (\>20 drinks/week)
Contact & Investigator
Matthias Liechti, Prof.MD
STUDY CHAIR
University Hospital of Basel
Frequently Asked Questions
Who can join the NCT07309471 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying LSD Reaction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07309471 currently recruiting?
Yes, NCT07309471 is actively recruiting participants. Contact the research team at matthias.liechti@usb.ch for enrollment information.
Where is the NCT07309471 trial being conducted?
This trial is being conducted at Basel, Switzerland.
Who is sponsoring the NCT07309471 clinical trial?
NCT07309471 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Matthias Liechti, Prof.MD at University Hospital of Basel. The trial plans to enroll 24 participants.